8-K: Regen Biopharma Issues 10 Million Shares to CEO for $50,000 in Accrued Salary, Signaling Financial Strain

Regen Biopharma, Inc. has issued 10 million common shares to its CEO, David R. Koos, to settle $50,000 of his accrued but unpaid salary, resulting in significant dilution and highlighting ongoing financial challenges.

Summary

• Regen Biopharma, Inc. issued 10,000,000 common shares to its Chief Executive Officer, David R. Koos, on June 10, 2025.
• The shares were issued to settle $50,000 of salary accrued but unpaid to Mr. Koos for services rendered between February 11, 2015, and January 22, 2020.
• Mr. Koos's employment agreement from February 10, 2015, stipulated a monthly salary of $15,000.
• The total accrued but unpaid salary due to Mr. Koos prior to January 22, 2020, was $457,113.19.
• After settling $50,000 with shares, $407,113.19 of Mr. Koos's accrued salary remains unpaid.
• The shares were issued as an unregistered sale of equity securities under Section 4(a)(2) of the Securities Act of 1933, with no underwriters or commissions paid.
• Following this issuance, Regen Biopharma, Inc. has 31,554,704 common shares outstanding as of June 10, 2025.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to extreme shareholder dilution for a minimal debt settlement, the implied very low valuation of the company's shares, and the indication of severe and ongoing financial distress given the inability to pay accrued executive salary in cash.

Positives

• The company settled a portion of its accrued salary debt ($50,000) without expending cash, which may alleviate immediate liquidity pressure.

Negatives

• The issuance of 10,000,000 shares to settle only $50,000 of debt implies an extremely low valuation per share ($0.005), indicating significant financial distress.
• Existing shareholders experienced substantial dilution, with the common shares outstanding increasing from an implied 21,554,704 to 31,554,704, representing approximately a 46.4% increase.
• A significant portion of the CEO's accrued salary ($407,113.19) remains unpaid, suggesting ongoing cash flow challenges and potential future equity issuances or debt obligations.
• The company's inability to pay cash salary for services rendered years ago (2015-2020) points to persistent financial difficulties.

Risks

• Significant shareholder dilution due to equity issuances at very low valuations.
• Ongoing financial instability and liquidity concerns, as evidenced by the inability to pay accrued salaries in cash.
• Potential for further equity issuances to settle remaining debts or fund operations, leading to additional dilution.
• Corporate governance concerns regarding the CEO settling his own accrued salary with company shares, especially at such a low implied valuation.
• The company's reliance on non-cash compensation methods may deter future talent or indicate a lack of investor confidence.

Future Outlook

The document does not provide explicit forward-looking statements or guidance regarding future financial performance or strategic initiatives. However, the transaction implies ongoing financial challenges that may impact future operations.

Management Comments

• David Koos, Chairman and Chief Executive Officer, signed the 8-K report on behalf of Regen Biopharma, Inc.

Industry Context

This type of equity issuance to settle accrued compensation is often observed in early-stage or financially distressed biotechnology companies that may lack sufficient cash flow to meet their obligations. It reflects a common strategy for micro-cap firms to manage liabilities without depleting scarce cash resources, though it comes at the cost of significant shareholder dilution.

Comparison to Industry Standards

• Issuing 10 million shares for a $50,000 debt settlement implies an extremely low valuation ($0.005 per share), which is significantly below typical valuations for publicly traded biopharma companies, even those in early clinical stages.
• While equity compensation is standard in the biotech industry, settling long-standing accrued salary with such a large number of shares for a relatively small cash equivalent value is indicative of severe financial constraints, unlike more established or well-funded peers.
• Companies like Moderna or BioNTech, even in their early stages, typically raised capital through more structured equity rounds at higher valuations or secured significant grants/partnerships, rather than settling executive compensation at such dilutive terms.

Corporate Governance

Legal Proceedings

• The settlement agreement specifies that all questions concerning its construction, validity, enforcement, and interpretation shall be governed by the internal laws of the State of California.
• It also states that the prevailing party in any action or proceeding to enforce the agreement shall be reimbursed for its attorneys' fees and other costs.

Related Party Transactions

• The company issued 10,000,000 common shares to David R. Koos, the company's Chief Executive Officer, in settlement of his accrued but unpaid salary. This constitutes a direct transaction with a related party.

Stakeholder Impact

• Shareholders: Experience significant dilution (approximately 46.4%) due to the issuance of 10 million shares, which implies a very low valuation for the company's stock.
• Employees (specifically the CEO): Received equity instead of cash for past services, indicating the company's cash constraints, though a substantial portion of the accrued salary remains unpaid.
• Creditors: While not directly impacted by this specific transaction, the company's inability to pay cash for accrued salary suggests broader financial weakness that could concern other creditors.

Next Steps

• The company will need to address the remaining $407,113.19 in unpaid accrued salary to Mr. Koos, which may involve further equity issuances or other forms of compensation.

Key Dates

Keywords

Biopharma, Equity Issuance, Common Stock, CEO Compensation, Debt Settlement, SEC Filing, 8-K, Unregistered Sale, Share Dilution, Financial Distress